MXPA04000870A - Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t. - Google Patents

Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.

Info

Publication number
MXPA04000870A
MXPA04000870A MXPA04000870A MXPA04000870A MXPA04000870A MX PA04000870 A MXPA04000870 A MX PA04000870A MX PA04000870 A MXPA04000870 A MX PA04000870A MX PA04000870 A MXPA04000870 A MX PA04000870A MX PA04000870 A MXPA04000870 A MX PA04000870A
Authority
MX
Mexico
Prior art keywords
lhrh
antagonists
improvement
cell mediated
mediated immunity
Prior art date
Application number
MXPA04000870A
Other languages
English (en)
Inventor
Peukert Manfred
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of MXPA04000870A publication Critical patent/MXPA04000870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere al uso de dosis apropiadas de un antagonista-LHRH para reducir los niveles de hormonas del sexo que proporciona un resultado en una regulacion de la poblacion de la celula-T en un individuo que sufre una enfermedad que respondera favorablemente a tal regulacion. Un antagonista-LHRH preferido es cetrorelix.
MXPA04000870A 2001-07-31 2002-07-30 Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t. MXPA04000870A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10137174A DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
PCT/EP2002/008459 WO2003011314A2 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists for the improvement of t-cell mediated immunity

Publications (1)

Publication Number Publication Date
MXPA04000870A true MXPA04000870A (es) 2004-06-03

Family

ID=7693650

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000870A MXPA04000870A (es) 2001-07-31 2002-07-30 Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.

Country Status (19)

Country Link
EP (1) EP1414481B1 (es)
JP (1) JP2005500348A (es)
KR (1) KR20040028957A (es)
CN (1) CN1525865A (es)
AR (1) AR034954A1 (es)
AT (1) ATE315400T1 (es)
BR (1) BR0211498A (es)
CA (1) CA2452524A1 (es)
DE (2) DE10137174A1 (es)
HR (1) HRP20040186B1 (es)
HU (1) HUP0401634A2 (es)
IL (1) IL159285A0 (es)
MX (1) MXPA04000870A (es)
NO (1) NO20040350L (es)
NZ (1) NZ531263A (es)
PL (1) PL364492A1 (es)
RU (1) RU2004106545A (es)
WO (1) WO2003011314A2 (es)
ZA (1) ZA200309889B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
JP2010538989A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｈｂｖ感染等の治療における治療剤としてのｎｆ−カッパーｂインヒビターｓｎ５０の使用、及び必要に応じたアンギオテンシンｉｉｉの使用
WO2009033725A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2379099A1 (en) * 2009-01-22 2011-10-26 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
WO2016030334A2 (en) 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CN107007814B (zh) * 2016-11-04 2020-03-17 中国科学院昆明动物研究所 西曲瑞克在制备治疗艾滋病的药物中的应用
CN108066763A (zh) * 2017-12-21 2018-05-25 陈敏 Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067123A1 (en) * 1989-09-25 1991-03-26 Esther M. Sternberg Evaluative means for detecting inflammatory reactivity and for predicting response to stress
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
WO1996003138A1 (en) * 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
AU3361695A (en) * 1994-08-10 1996-03-07 Dezso Gaal Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof
AU4459196A (en) * 1995-01-23 1996-08-14 Takeda Chemical Industries Ltd. Sustained-release preparation and use
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
EP1032397A1 (en) * 1997-11-24 2000-09-06 University Of Florida Research Foundation, Inc. Testosterone inhibitors and use for the protection of neurons
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
WO2001078780A1 (fr) * 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Agents preventifs/remedes pour la maladie d'alzheimer
CA2462046A1 (en) * 2000-10-13 2002-04-18 Monash University Improvement of graft acceptance through manipulation of thymic regeneration
RU2319501C2 (ru) * 2001-04-30 2008-03-20 Центарис Гмбх Способ лечения болезни альцгеймера
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence

Also Published As

Publication number Publication date
HUP0401634A2 (hu) 2004-12-28
ZA200309889B (en) 2004-02-19
CN1525865A (zh) 2004-09-01
PL364492A1 (en) 2004-12-13
EP1414481B1 (en) 2006-01-11
IL159285A0 (en) 2004-06-01
JP2005500348A (ja) 2005-01-06
AR034954A1 (es) 2004-03-24
DE10137174A1 (de) 2003-02-13
WO2003011314A2 (en) 2003-02-13
EP1414481A2 (en) 2004-05-06
DE60208701D1 (de) 2006-04-06
CA2452524A1 (en) 2003-02-13
WO2003011314A3 (en) 2003-10-16
NO20040350L (no) 2004-01-26
RU2004106545A (ru) 2005-04-10
KR20040028957A (ko) 2004-04-03
DE60208701T2 (de) 2006-08-10
HRP20040186B1 (en) 2007-05-31
ATE315400T1 (de) 2006-02-15
BR0211498A (pt) 2004-08-17
NZ531263A (en) 2005-05-27
HRP20040186A2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
WO2004014953A3 (en) Anti-myelin associated glycoprotein (mag) antibodies
CA97478S (en) Oxygen delivery device
MY136707A (en) Thrombopoietin mimetics
YU68002A (sh) Modifikovani faktor viii
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
HK1072000A1 (en) Treatment of alzheimer's diseases with intemediatedoses of lhrh antagonists
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
MXPA04000870A (es) Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t.
UA85368C2 (ru) Применение остеопонтина для лечения и/или предотвращения неврологического заболевания
EP1282432A4 (en) METHOD OF USING ZONULIN PEPTIDE ANTAGONISTS TO PREVENT OR DELAY THE APPEARANCE OF DIABETES
RS97604A (en) New etonogestrel esters
CA98892S (en) Lobby dust pan
MY137620A (en) Therapeutic treatment
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
YU29804A (sh) Upotreba aktivatora gp-130 u dijabetskoj neuropatiji
IL147188A (en) Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases
HK1054324A1 (en) The treatment of inflammatory disorders
CA99734S (en) Safety cone
MD2053B1 (en) Remedy with interferon inducing action
CA98438S (en) Spout
DE60212130D1 (en) Carvedilolpolymorph
IL137426A (en) Joystick with a microphone
ES2195742A1 (es) Elemento para ayudar a la cementacion de protesis dentales fijas.
AU147414S (en) Central vacuum unit upper portion
PT1438341E (pt) Anticorpos que estimulam a producao de il-1ra